Zusammenfassung
Somatostatinanaloga sind eine Therapieoption für Patienten mit endokrinen Störungen, die mit einer chronischen Überproduktion von Wachstumshormon (GH) und Insulin-Like Growth Factor 1 (IGF-1) einhergehen. Diese Faktoren spielen auch in der Pathogenese der diabetischen Retinopathie eine wichtige Rolle. Die in der Retina exprimierten Somatostatinrezeptoren sind daher als Zielmoleküle für den Einsatz von Somatostatinanaloga in der Behandlung von vaskulären Netzhauterkrankungen, wie der diabetischen Retinopathie, hervorragend geeignet. Das Somatostatinanalogon Octreotid ist ein vielversprechendes Medikament mit guter Verträglichkeit zur Behandlung der fortgeschrittenen diabetischen Retinopathie und des diabetischen Makulaödems. Es kann die lokale und systemische Produktion von GH und IGF-1 und damit deren angiogene Effekte hemmen. Ergebnisse von Tierexperimenten und klinischen Studien an Patienten mit diabetischer Retinopathie weisen darauf hin, dass Octreotid den Krankheitsverlauf hinauszögern und bis zu einem gewissen Grad die Retinopathie verbessern kann.
Abstract
Somatostatin analogues are a therapeutic option in patients with chronic overproduction of growth hormon (GH) and insulin-like growth factor 1 (IGF-1). These factors are also involved in the pathogenesis of diabetic retinopathy. Somatostatin receptors are expressed in the retina and are therefore possible targets of somatostatin analogues in the treatment of retinal vascular diseases like diabetic retinopathy. The somatostatin analogue octreotide has shown promise as a safe and effective treatment for advanced diabetic retinopathy and diabetic macular edema. The compound blocks the local and systemic production of GH and IGF-1, and thus inhibits the angiogenic effect. Evidence from animal models, and clinical trials in patients with diabetic retinopathy, suggest that octreotide can delay, and to some extent reverse diabetic retinopathy.
Literatur
Böhm BO, Lang GK, Jehle PM, Feldmann B, Lang GE (2001) Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 33:300–306
Böhm BO, Lang GE, Volpert O et al (2003) Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia 46:394–400
Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J et al (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77–79
Danis RP, Bingaman DP (1997) Insulin-like growth factor-1 retinal microangiopathy in the pig eye. Ophthalmology 104:1661–1669
Davis MI, Wilson SH, Grant MB (2001) The therapeutic problem of proliferative diabetic retinopathy: Targeting somatostatin receptors. Horm Metab Res 33:295–299
Grant MB, Mames RN, Fitzgerald C, Hahariwala KM, Cooper-DeHoff R, Caballero S, Estes KS (2000) The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy. Diabetes Care 23:504–509
Grant MB, Caballero S, Smith LEH (2002) Somatostatin in diabetic eye diseases. In: The expanding role of octreotide II:Advances in Endocrinology and eye diseases. Eds Lamberts SWJ, Ghigo E, DioScientifica Ltd, Bristol. 165–184
Joussen AM, Fauser S, Krohne TU, Lemmen KD, Lang GE, Kirchhof B (2003) Diabetische Retinopathie: Pathophysiologie und Therapie einer hypoxieinduzierten Entzündung. Ophthalmologe 100:363–370
Lang GE, Kampmeier J (2002) Die Bedeutung der Proteinkinase C in der Pathophysiologie der diabetischen Retinopathie. Klin Monatsbl Augenheilkd 219:769–776
Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB (1995) The somatostatin receptor family. Life Sci 57:1249–1265
Poulsen JE (1953) The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmond‚s disease. Diabetes 2:7–12
Poulsen JE (1966) Diabetes and anterior pituitary insufficiency: final course and postpartum study of a diabetic patient with Sheehan‘s syndrome. Diabetes 15:73–77
Spranger J, Mohlig M, Osterhoff M, Bühnen J, Blum WF, Pfeiffer AFH (2001) Retinal photocoagulation does not influence intraocular levels of IGF-I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy—evidence for combined treatment of PDR with somatostatin analogues and retinal photocoagulation? Horm Met Res 33:312–316
Spraul CW, Baldysiak-Figiel A, Lang GK, Lang GE (2002) Octreotide inhibits growth factor-induced bovine choriocapillary endothelial cells in vitro. Graefes Arch Clin Exp Ophthalmol 240:227–231
Van Hagen PM, Baarsma GS, Mooy CM, Ercoskan EM, Averst E, Hofland LJ, Lamberts SWJ, Kuijpers RWAM (2000) Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol 143:43–51
Van Hagen PM, Kuijpers RWAM, Baarsma GS (2002) Somatostatin and somatostatin receptors in the retina. In: The expanding role of octreotide II:Advances in Endocrinology and eye diseases. Eds Lamberts SWJ, Ghigo E, DioScientifica Ltd, Bristol. 143–147
Van Hagen PM, Kuijpers RWAM, ter Averst E, Hofland LJ, Baarsma GS (2002) The clinical application of somatostatin analogues in retinal diseases. In: The expanding role of octreotide II:Advances in Endocrinology and eye diseases. Eds Lamberts SWJ, Ghigo E, DioScientifica Ltd, Bristol. 143–147
Wachtmeister L (1983) The action of peptides on the Mudpuppy electrogram. Experimental Eye Research 33:429–437
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lang, G.E. Therapie der diabetischen Retinopathie mit Somatostatinanaloga. Ophthalmologe 101, 290–293 (2004). https://doi.org/10.1007/s00347-003-0903-2
Issue Date:
DOI: https://doi.org/10.1007/s00347-003-0903-2